In contrast, in tumor-bearing control mice and mice treated only with anti-CTLA-4 where tumor burden was high, ICOS expression was increased on both FoxP3+ Tregs and FoxP3− Teff cells (Fig. 6b, c). The gene discussed is FOXP3; the disease is neoplasm.